Drugs to Watch: Current Clinical Trials in Hematology/Oncology

The oncology pipeline is robust, according to Andrea Prince, PharmD, BCACP, a hematology/oncology clinical pharmacist at Northwestern Medicine. During her presentation at the 2023 American Society of Health-System Pharmacists (ASHP) Summer Meetings and Exhibition, Prince reviewed several notable drugs in the pipeline, including several that are first in class therapies and others with a novel mechanism of action.

References

1. Rim MH, Prince A. Specialty pharmacy pipeline updates I: Expansion of hematology/oncology therapies. Presented at: 2023 American Society of Health-System Pharmacists Summer Meetings and Exhibition; June 10-14, 2023; Baltimore, MD.

2. Erba H, Montesinos P, Vrhovac R, et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single- agent continuation in patients aged 18-75 yaers with newly diagnosed FLT3-ITD+ AML. Presented at: European Hematology Congress 2022; June 9-12, 2022; Vienna, Austria. https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html  

3. Verstovesk S, Gerds AT, Vannucchi AM, et al; MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomized, controlled, phase 3 study. Lancet. 2023;401(10373):269-280. doi:10.1016/S0140-6736(22)02036-0 

4. Dasari NA, Lonardi S, Garcia-Carbonero R, et al. FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruqintinib in patients with refractory metastatic colorectal cancer. Annals of Oncology. 2022;33 (suppl_7):S808-S869. doi:10.1016/annonc/annonc1089

5. Talquetamab generates high response rate in relapsed or refractory multiple myeloma. The ASCO Post. December 11, 2022. Updated Decmeber 19, 2022. Accessed June 12, 2023. https://ascopost.com/news/december-2022/talquetamab-generates-high-response-rate-in-relapsed-or-refractory-multiple-myeloma/

6. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231. doi:10.1056/NEJMoa2206913

7. Mellinghoff IK, Van Den Bent MJ, Clarke JL. INIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation. J Clin Oncol 38: 2020 (suppl; abtsr TPS2574). doi:10/1200/JCO.2020.38.15_suppl.TPS2574

8. Mellinghoff IK, Van Den Bent MJ, Blumenthal DT. INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. J Clin Oncol 41, 2023 (suppl 17; abstr LBA1). doi:10.1200/JCO.2023.41.17_suppl.LBA1